Mineralys Therapeutics, Inc. Common Stock
$ 30.42
11.35%
15 Apr - close price
- Market Cap 2,252,587,000 USD
- Current Price $ 30.42
- High / Low $ 31.11 / 27.00
- Stock P/E N/A
- Book Value 7.93
- EPS -2.29
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.37 %
- 52 Week High 47.65
- 52 Week Low 12.59
About
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
Analyst Target Price
$49.38
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-18 | 2025-11-11 | 2025-08-12 | 2025-05-12 | 2025-02-12 | 2024-11-11 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-07 | 2023-08-07 | 2023-05-15 |
| Reported EPS | -0.4 | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.7 | -0.61 | -0.57 | -0.31 | -0.51 |
| Estimated EPS | -0.94 | -0.64 | -0.74 | -0.98 | -1.08 | -0.83 | -0.7 | -0.67 | -0.82 | -0.76 | -0.72 | -0.89 |
| Surprise | 0.54 | 0.12 | 0.08 | 0.19 | 0.1 | -0.3 | -0.13 | -0.03 | 0.21 | 0.19 | 0.41 | 0.38 |
| Surprise Percentage | 57.4468% | 18.75% | 10.8108% | 19.3878% | 9.2593% | -36.1446% | -18.5714% | -4.4776% | 25.6098% | 25% | 56.9444% | 42.6966% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.51 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLYS
2026-04-14 18:40:03
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 2,170 shares for $59,414 following the exercise of options. The sale was executed under a Rule 10b5-1 trading plan, and Rodman now directly owns 76,140 shares. This comes as MLYS stock has seen a 95% return over the past year and trades above its InvestingPro Fair Value.
2026-04-14 01:09:32
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 2,170 shares for $59,414 and exercised options for an equal number of shares. This transaction follows the company's strong stock performance and recent positive earnings report. Analyst ratings for MLYS shares are mixed, with some firms raising price targets due to drug development progress while others maintain a Hold rating due to strategic uncertainties.
2026-04-14 01:09:32
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised stock options for 2,170 shares at $16.00 per share and subsequently sold these shares in an open-market transaction at $27.38 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, Rodman directly holds 76,140 shares of Mineralys Therapeutics common stock.
2026-04-13 20:09:33
Jon Congleton reported two Rule 144 transactions involving the sale of Mineralys Therapeutics common stock, totaling 16,236 shares for $529,639.51 on January 12, 2026, and 75,000 shares for $1,970,520.69 on March 31, 2026. Additionally, the filing disclosed the vesting of 15,730 restricted share units on April 10, 2026, as part of the issuer's equity compensation plan. This information is derived from a Form 144 SEC filing by Mineralys Therapeutics.
2026-04-13 20:09:32
Mineralys Therapeutics, Inc. (MLYS) has filed a Form 144 indicating an affiliate's proposed sale of 14,058 shares of common stock for $373,086.81, scheduled for April 13, 2026, via a broker-assisted cashless exercise. The filing also details numerous open-market dispositions by David Rodman, including repeated smaller sales throughout January to April 2026, consistent with phased dispositions or mechanics tied to option exercises. Securities Compliance Analyst and Corporate Insider Transactions Specialist noted the neutrality of the filing, interpreting the transactions as standard resales and phased dispositions rather than a single large liquidation.
2026-04-11 10:30:00
This article from Stock Traders Daily discusses Mineralys Therapeutics Inc. (NASDAQ: MLYS), highlighting strong sentiment across all horizons and a breakdown currently underway. It provides detailed institutional trading strategies including long, breakout, and short positions, along with multi-timeframe signal analysis for various time horizons. The analysis suggests elevated downside risk due to the lack of additional long-term support signals.
